Literature DB >> 27405485

Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Shivaprasad H Venkatesha1, Steven Dudics1, Brian Astry1, Kamal D Moudgil2.   

Abstract

Celastrol is a bioactive compound derived from traditional Chinese medicinal herbs of the Celastraceae family. Celastrol is known to possess anti-inflammatory and anti-oxidant activities. Our studies have highlighted the immunomodulatory attributes of celastrol in adjuvant-induced arthritis (AA), an experimental model of human rheumatoid arthritis (RA). RA is an autoimmune disease characterized by chronic inflammation of the synovial lining of the joints, leading eventually to tissue damage and deformities. Identification of the molecular targets of celastrol such as the NF-κB pathway, MAPK pathway, JAK/STAT pathway and RANKL/OPG pathway has unraveled its strategic checkpoints in controlling arthritic inflammation and tissue damage in AA. The pathological events that are targeted and rectified by celastrol include increased production of pro-inflammatory cytokines; an imbalance between pathogenic T helper 17 and regulatory T cells; enhanced production of chemokines coupled with increased migration of immune cells into the joints; and increased release of mediators of osteoclastic bone damage. Accordingly, celastrol is a promising candidate for further testing in the clinic for RA therapy. Furthermore, the results of other preclinical studies suggest that celastrol might also be beneficial for the treatment of a few other autoimmune diseases besides arthritis. © FEMS 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  autoimmune diseases; celastrol; immune modulation; inflammation; natural products

Mesh:

Substances:

Year:  2016        PMID: 27405485      PMCID: PMC5985506          DOI: 10.1093/femspd/ftw059

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  132 in total

1.  Ulcerative colitis: current treatment strategies and future prospects.

Authors:  Sagar Garud; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

2.  Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.

Authors:  Lin-Li Zhou; Zhi-Xiu Lin; Kwok-Pui Fung; Christopher H K Cheng; Chun-Tao Che; Ming Zhao; Shi-Hua Wu; Zhong Zuo
Journal:  Eur J Pharmacol       Date:  2011-09-21       Impact factor: 4.432

3.  Transplantation tolerance induced by regulatory T cells: in vivo mechanisms and sites of action.

Authors:  Dela Golshayan; Jean-Christophe Wyss; Caroline Wyss Abulker; Stephan C Schaefer; Robert I Lechler; Hans-Anton Lehr; Manuel Pascual
Journal:  Int Immunopharmacol       Date:  2009-01-09       Impact factor: 4.932

Review 4.  Systemic lupus erythematosus.

Authors:  Larissa Lisnevskaia; Grainne Murphy; David Isenberg
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

5.  Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.

Authors:  Jeong-Hyung Lee; Tae Hyeon Koo; Hyunkyung Yoon; Haeng Sun Jung; Hui Zi Jin; Kyeong Lee; Young-Soo Hong; Jung Joon Lee
Journal:  Biochem Pharmacol       Date:  2006-09-18       Impact factor: 5.858

Review 6.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

Review 7.  Evidence that cytokines play a role in rheumatoid arthritis.

Authors:  Fionula M Brennan; Iain B McInnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

8.  TGF-beta promotes Th17 cell development through inhibition of SOCS3.

Authors:  Hongwei Qin; Lanfang Wang; Ting Feng; Charles O Elson; Sandrine A Niyongere; Sun Jung Lee; Stephanie L Reynolds; Casey T Weaver; Kevin Roarty; Rosa Serra; Etty N Benveniste; Yingzi Cong
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

Review 9.  Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets.

Authors:  Daniel E Furst; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2014-01-08       Impact factor: 7.580

Review 10.  Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky.

Authors:  Jim Middleton; Laure Americh; Regis Gayon; Denis Julien; Luc Aguilar; Francois Amalric; Jean-Philippe Girard
Journal:  Arthritis Res Ther       Date:  2004-03-08       Impact factor: 5.156

View more
  36 in total

1.  Comparative transcriptomics and network pharmacology analysis to identify the potential mechanism of celastrol against osteoarthritis.

Authors:  Siming Dai; Hui Wang; Meng Wang; Yue Zhang; Zhiyi Zhang; Zhiguo Lin
Journal:  Clin Rheumatol       Date:  2021-04-19       Impact factor: 2.980

2.  Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology.

Authors:  Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Inflamm Res       Date:  2019-02-28       Impact factor: 4.575

3.  Celastrol attenuates the remodeling of pulmonary vascular and right ventricular in monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Huayang Li; Quan Liu; Yuan Yue; Shunjun Wang; Suiqing Huang; Lin Huang; Li Luo; Yitao Zhang; Zhongkai Wu
Journal:  Cardiovasc Diagn Ther       Date:  2022-02

4.  Celastrol improves self-renewal and differentiation of human tendon-derived stem cells by suppressing Smad7 through hypoxia.

Authors:  Tianyi Wu; Shenghe Liu; Gen Wen; Jia Xu; Yaling Yu; Yimin Chai
Journal:  Stem Cell Res Ther       Date:  2017-12-04       Impact factor: 6.832

5.  The Calcium-Induced Regulation in the Molecular and Transcriptional Circuitry of Human Inflammatory Response and Autoimmunity.

Authors:  Ivo R de Seabra Rodrigues Dias; Simon W F Mok; Flora Gordillo-Martínez; Imran Khan; Wendy W L Hsiao; Betty Y K Law; Vincent K W Wong; Liang Liu
Journal:  Front Pharmacol       Date:  2018-01-08       Impact factor: 5.810

Review 6.  Natural Products with Toll-Like Receptor 4 Antagonist Activity.

Authors:  Monica Molteni; Annalisa Bosi; Carlo Rossetti
Journal:  Int J Inflam       Date:  2018-03-01

7.  Celastrol targets adenylyl cyclase-associated protein 1 to reduce macrophages-mediated inflammation and ameliorates high fat diet-induced metabolic syndrome in mice.

Authors:  Yuyu Zhu; Ning Wan; Xinni Shan; Guoliang Deng; Qiang Xu; Hui Ye; Yang Sun
Journal:  Acta Pharm Sin B       Date:  2020-12-15       Impact factor: 11.413

8.  A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE.

Authors:  Hsi-Ju Wei; Tej K Pareek; Qi Liu; John J Letterio
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 9.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.

Authors:  Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri
Journal:  Vaccines (Basel)       Date:  2017-10-04

10.  Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/macrophage M2 polarization.

Authors:  Mei Jiang; Xinghui Liu; Denghai Zhang; Ying Wang; Xiaoxia Hu; Fengxia Xu; Mingming Jin; Fanfan Cao; Limin Xu
Journal:  J Neuroinflammation       Date:  2018-03-14       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.